KeyNeurotek opens Leipzig research unit

Magdeburg, Germany-based biotechnology firm KeyNeurotek Pharmaceuticals, which is focused on developing and marketing drugs  against autoimmune diseases and degenerative disorders of the central  nervous system, has established new research facilities in Leipzig.

As part of the expansion of its business activities, the firm's  subsidiary, KeyNeurotek Pharma, has opened laboratories and offices at  Leipzig's Bio City, to further expand its existing research network to  institutions in this area. The R&D activities in Leipzig will focus on  several preclinical projects, as well as clinical development  activities in the area of urinary incontinence.

At the same time, all CNS-related development activities of the parent  company will be expanded at its Magdeburg site. The firm's lead product  KN38-7271, a dual cannabinoid CB1/CB2 receptor agonist, is currently  being investigated in a multinational Phase IIa study in comatose  traumatic brain injury patients. Study results for the compound, which  has European orphan status, are expected this summer, the firm said.